News Board

Stellantis told investors 2025 would be the year growth came back. Electrification was “growing,” margins were supposed to recover, and management said the company was built to win that shift. But behind the scenes, the complaint says Stellantis had badly misread EV demand and wasn’t positioned to turn that push into real profit. In February...Read more

Upstart told investors its AI was getting smarter. Model 22 was supposed to approve more borrowers, lift conversion rates, and push revenue past $1 billion. For months, executives pointed to AI breakthroughs and raised guidance again and again. But behind the scenes, the lawsuit says that same model was overreacting to macro signals, turning far...Read more

On May 27, 2026, two Co-Lead Plaintiffs were appointed in the class action lawsuit captioned Ortolani v. Plug Power Inc., et al., 1:26-cv-00165-MAD-DJS. United States Magistrate Judge in the Northen District of New York, Daniel Stewart, signed the order that also approved Levi & Korsinsky, LLP and Pomerantz LLP as Co-Lead Counsel in the action....Read more

AMENDED SUMMARY NOTICE OF SETTLEMENT Teuza v. Lindon et al., C.A. NO. 2022-0130-BWD (Del. Ch.) The Court of Chancery of the State of Delaware has directed the dissemination of the following Amended Summary Notice for the above-captioned stockholder class action. The full Notice and related documents are available at https://www.bionessstockholdersettlement.com/ . Amended Summary Notice

ImmunityBio told investors it was sitting on a breakthrough. A cancer treatment with massive potential. Even framed as a path toward a cure. But that promise did not match reality. In January 2026, the company’s top executive went on a podcast claiming its drug Anktiva could treat all cancers and even prevent cancer. Big statements....Read more

Super Micro told investors it was riding the AI wave. Record demand. Explosive growth. Billions in revenue. But behind the scenes, a very different story was unfolding. Starting in April 2024, the company reported massive sales driven by AI servers and global demand. Executives pointed to strong growth across the U.S. and Asia and kept...Read more

Atara told investors it was on the verge of a breakthrough. A first of its kind cancer therapy. Strong data. FDA approval in sight. But behind the scenes, serious problems were building. In May 2024, Atara submitted its FDA application, claiming promising trial results and a smooth path forward. By July, the FDA granted priority...Read more

Coty told investors a comeback was already underway. Growth was coming back. Profits were set to rebound. Everything looked on track. But behind the scenes, key parts of the business were already under pressure. In November 2025, Coty promised improving sales, strong fragrance demand, and a return to growth by the second half of 2026....Read more

Lufax told investors its financials were strong. Controls were effective. Profits were accurate. But behind the scenes, the financials were misstated. In April 2023 and again in April 2024, Lufax filed annual reports claiming solid internal controls and accurate financials. Executives signed off. Everything looked clean. But the complaint says controls were deficient and financial...Read more

Hercules Capital told investors it had a disciplined system. Rigorous due diligence. Careful valuations. A growing portfolio. But the story investors got… may not have been the real one. From May 2025 through early 2026, the company reported rising portfolio values and steady net asset value, even highlighting what it called a multi step, carefully...Read more

Power Solutions told investors it was tapping into booming data center demand. High growth. Higher margins. A booming future. But behind the scenes, that story was starting to crack. In May 2025, the company reported record results and strong demand from data centers. By August, executives doubled down, pointing to strong demand and growth tied...Read more

Concorde told investors it offered technology-driven security services with recurring revenue. But according to a recently filed complaint, a coordinated promotion scheme was driving the stock. In April 2025, Concorde went public at $4 a share, highlighting recurring revenue and technology-based services. By June, executives were still touting growth and new contracts. But according to...Read more

On May 5, 2026, two Co-Lead Plaintiffs were appointed in the class action lawsuit captioned Diez v. Richtech Robotics Inc., et al., 2:26-cv-00231. United States Magistrate Judge in the District of Nevada, Maximiliano D. Couvillier III, signed the order that also approved Levi & Korsinsky, LLP and Hagens Berman Sobol Shapiro LLP as Co-Lead Counsel...Read more

Alight told investors a new era had arrived. A seasoned CEO. Strong growth. Reliable dividends. A steady path forward. But behind the scenes, that story was already breaking down. In November 2024, Alight promised improving margins, growing pipeline and improving bookings trends, and a consistent return of capital. By February 2025, they doubled down with...Read more

Gartner told investors growth was accelerating. Projected accelerating contract value growth. Pointing to a path toward double-digit growth. But that story started to crack. In February 2025, executives promised contract value growth would climb toward 12 to 16% in a normal environment. By May, they maintained that outlook, even as macro conditions became more challenging....Read more